Accepted Manuscript

Mapping of drug distribution in the rabbit liver tumor model by complementary fluorescence and mass spectrometry imaging

Katrin Fuchs, Andras Kiss, Pierre E. Bize, Rafael Duran, Alban Denys, Gérard Hopfgartner, Gerrit Borchard, Olivier Jordan

PII: S0168-3659(17)30943-4

DOI: doi:10.1016/j.jconrel.2017.10.042

Reference: COREL 9029

To appear in: Journal of Controlled Release

Received date: 13 July 2017 Revised date: 24 October 2017 Accepted date: 30 October 2017

Please cite this article as: Katrin Fuchs, Andras Kiss, Pierre E. Bize, Rafael Duran, Alban Denys, Gérard Hopfgartner, Gerrit Borchard, Olivier Jordan, Mapping of drug distribution in the rabbit liver tumor model by complementary fluorescence and mass spectrometry imaging. The address for the corresponding author was captured as affiliation for all authors. Please check if appropriate. Corel(2017), doi:10.1016/j.jconrel.2017.10.042

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



ACCEPTED MANUSCRIPT

Mapping of Drug Distribution in the Rabbit Liver Tumor Model by Complementary

Fluorescence and Mass Spectrometry Imaging

Katrin Fuchs^{a,+}, PhD, Andras Kiss^{b,+}, PhD, Pierre E. Bize^c, MD, Rafael Duran^c, MD, Alban Denys^c, MD, Gérard Hopfgartner^b, PhD, Gerrit Borchard^a, PhD, Olivier Jordan^{a,*}, PhD

- ^a School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Geneva, Switzerland
- ^b Life Sciences Mass Spectrometry, Department of Analytical and Inorganic Chemistry, University of Geneva, Geneva, Switzerland
- ^cDepartments of Radiology and Interventional Radiology, CHUV Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

*Corresponding author:

Olivier Jordan
School of Pharmaceutical Sciences
University of Geneva, University of Lausanne
1, Rue Michel-Servet
1211 Geneva 4
Switzerland
olivier.jordan@uniqe.ch, Tel.: +41 22 379 65 86

Conflict of interest: AD is a contracted consultant for BTG, Farnham, UK. Patent WO 2012/073188 A1 was issued and licensed to BTG by AD, PEB, OJ. All other authors do not declare a conflict of interest.

Financial support: The animal study was partially funded by a research grant from Biocompatibles Ltd./BTG, Farnham, UK to AD, PEB and OJ.

Abbreviations: DEB(s): drug-eluting bead(s), TACE: transarterial chemoembolization, MALDI-SRM/MSI: matrix-assisted laser desorption ionization with selected reaction monitoring mass spectrometry imaging, FITC: Fluorescein isothiocyanate, LC-MS/MS: liquid chromatography with tandem mass spectrometry detection, IC₅₀: half maximal inhibitory concentration, ROI: region of interest, LOD: limit of detection

Keywords: fluorescence imaging; MALDI-SRM mass spectrometry imaging; transarterial chemoembolization; sunitinib; drug-eluting beads; biodistribution

Author's contributions: Animal study: PEB, RD, AD, OJ; DEBs preparation, Tissue sectioning, Fluorescence imaging: KF, OJ, GB; MSI: AK, GH

Compound: Sunitinib: PubChem CID 5329102

[†]Equal contribution

Download English Version:

https://daneshyari.com/en/article/7860624

Download Persian Version:

https://daneshyari.com/article/7860624

<u>Daneshyari.com</u>